Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924196 | 0.85 | P2RX7 (0.33) | P2RX7ITGB3ITGA2BMCHR1DPP4 | |
| SCHEMBL16415209 | 0.79 | ITGB3 (0.39) | P2RX7ITGB3ITGA2BMCHR1DPP4 | |
| SCHEMBL19439275 | 0.77 | ITGB3 (0.38) | P2RX7ITGB3ITGA2BMCHR1DPP4 | |
| SCHEMBL3179062 | 0.77 | MCHR1 (0.43) | MCHR1DPP4HRH3 | |
| SCHEMBL4014309 | 0.75 | PARP1 (0.40) | P2RX7ITGB3ITGA2BMCHR1 | |
| SCHEMBL20571751 | 0.75 | P2RX7 (0.51) | P2RX7ITGB3ITGA2B | |
| SCHEMBL13783754 | 0.74 | — | — | |
| SCHEMBL16416532 | 0.72 | P2RX7 (0.36) | P2RX7ITGB3ITGA2BDPP4 | |
| SCHEMBL2932063 | 0.71 | DPP4 (0.46) | DPP4 | |
| SCHEMBL12495357 | 0.71 | TSHR (0.43) | P2RX7ITGB3ITGA2BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20050261496-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261496-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | P2RX7 993/4885ITGB3 3585/4885ITGA2B 4199/4885 |
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | P2RX7 993/4885ITGB3 3585/4885ITGA2B 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.